Dáil Éireann Debate, Wednesday - 1 May 2024
296. Deputy Róisín Shortall asked the Minister for Health to provide an update on implementation of each of the recommendations from the review of governance arrangements to support the HSE drug reimbursement process, prepared by a company (details supplied); and if he will make a statement on the matter. [19698/24]
View answerIn February 2023, I published the Mazars Review which examined the governance arrangements around the HSE’s Drug Pricing and Reimbursement Process. The Report found that the reimbursement process is operating in line with the legislation and that it is delivering results in line with international norms. I fully support the recommendations contained in the Mazars report around improving the process, increasing transparency, providing easier access, and supporting value for money.
An implementation group has been established between my Department and the HSE to consider and progress the various recommendations contained in the Report. The membership of the Group includes representatives of the Drugs Group, the HSE, the NCPE, and the Department of Health. The Working Group has met frequently since its establishment, to consider the involvement of patients, industry, and clinicians, in each stage of the reimbursement process.
The Group has conducted two rounds of targeted stakeholder consultation. The insights gained from stakeholders have been considered by the Group as it continues its work on progressing the various recommendations of the Review. The Group’s work is now nearing completion and a report on this will be submitted to me in the coming weeks.
